Last edition
News about "Matthew B. Klein"
PTC Therapeutics Secures US FDA Approval for SEPHIENCE
PTC Therapeutics has received FDA approval for SEPHIENCE (sepiapterin) to treat sepiapterin-responsive phenylketonuria (PKU) in patients aged one month and older, offering a new therapy for managing this rare metabolic disorder.
Matthew B. Klein | 29/07/2025 | By Mrinmoy Dey | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members